Structure Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences
Rhea-AI Summary
Structure Therapeutics (NASDAQ: GPCR), a clinical-stage biopharmaceutical company focused on developing oral small molecule therapeutics for metabolic diseases and obesity, has announced its participation in two major healthcare investor conferences.
Management will present at the Cantor Global Healthcare Conference on September 3 at 3:55 p.m. ET and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 10 at 10:45 a.m. ET. Both events will be held in New York and will feature fireside chats along with one-on-one meetings. Webcasts will be available on the company's investor relations website for 90 days.
Positive
- None.
Negative
- None.
SAN FRANCISCO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced that management will participate in two upcoming healthcare conferences in September.
| Cantor Global Healthcare Conference | ||
| Format: | Fireside chat and 1x1 meetings | |
| Date/time: | Wednesday, September 3 at 3:55 p.m. ET | |
| Location: | New York, NY | |
Morgan Stanley 23rd Annual Global Healthcare Conference | ||
| Format: | Fireside chat and 1x1 meetings | |
| Date/time: | Wednesday, September 10 at 10:45 a.m. ET | |
| Location: | New York, NY | |
The live and archived webcasts will be accessible from the company’s website at https://ir.structuretx.com/events-presentations/events and replays will be available for 90 days.
About Structure Therapeutics
Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, the Company has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage oral small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more patients around the world. For additional information, please visit www.structuretx.com.
Investors:
Danielle Keatley
Structure Therapeutics Inc.
ir@structuretx.com
Media:
Dan Budwick
1AB
Dan@1abmedia.com
FAQ
When is Structure Therapeutics (GPCR) presenting at the Cantor Global Healthcare Conference?
When is Structure Therapeutics (GPCR) presenting at the Morgan Stanley Healthcare Conference?
How can investors access Structure Therapeutics' (GPCR) conference presentations?
What type of company is Structure Therapeutics (GPCR)?
